CD274 and neoplasm: In the CheckMate 141 trial, positive tumor PD-L1 expression appeared to have conferred a numerically higher survival benefit in patients receiving nivolumab vs IC therapy [HR = 0.55 (95% CI, 0.36–0.83) in patients with tumors expressing ≥1% PD-L1 vs HR = 0.89 (95% CI, 0.54–1.45) in patients with tumors expressing <1% PD-L1] (44, 65).